SNDX News and Press, Syndax Pharmaceuticals Inc. From 03/01/21

Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 PR Newswire WALTHAM, Mass. , March 1, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SND...

Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index WALTHAM, Mass. , Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pip...

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody for GVHD. Syndax has a pipeline of 3 therapeutics (SNDX-5613, SNDX-6352, Entinostat) with 2 s...

Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass , Dec. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage b...

Syndax Pharmaceuticals (SNDX) has priced its public offering of 5,434,783 common shares at $23.00/share, for expected gross proceeds of ~$125M.Underwriters' over-aalotment is an additional 815,217 shares. Closing date is December 11. For further details see: Syndax prices equity offerin...

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this event. For further details see: Syndax Pharmaceuticals (SNDX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Syndax Pharmaceuticals (SNDX) seeks to offer and sell shares in an underwritten public offering; underwriters granted 30-day option to purchase additional 15% of shares.Actual size or offer terms have not yet been disclosed. For further details see: Syndax Pharmaceutical readies pr...

Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD WALTHAM, Mass. , Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmac...

Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts PR Newswire WALTHAM, Mass., Nov. 30, 2020 WALTHAM, Mass. , Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nas...

Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference PR Newswire WALTHAM, Mass., Nov. 11, 2020 WALTHAM, Mass. , Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage...